Related Experiment Videos
Bradykinin receptor antagonists
1Division of Medicinal Chemistry, Hoechst Marion Roussel Germany GmbH, Chemical Research, D-65926 Frankfurt/Main, Germany. holger.heitsch@hmrag.com
Idrugs : the Investigational Drugs Journal
|August 30, 2005
Summary
Researchers reviewed patent literature on bradykinin B2 receptor antagonists from 1994-1998. The rise of non-peptide antagonists shows progress in understanding bradykinin receptor antagonism in disease.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Drug Discovery
Background:
- Bradykinin B2 receptors play a role in human pathophysiology.
- Potent and selective peptide antagonists for bradykinin receptors are known.
- Patent literature reveals ongoing research into novel antagonists.
Purpose of the Study:
- To review recent patent literature concerning bradykinin B2 receptor antagonists.
- To assess the progress in the development of non-peptide bradykinin B2 receptor antagonists.
- To highlight the significance of these developments for understanding bradykinin's role in disease.
Main Methods:
- Comprehensive review of patent applications filed between 1994 and 1998.
- Analysis of disclosed chemical structures and claimed therapeutic applications.
- Identification of trends in antagonist development (peptide vs. non-peptide).
Main Results:
- A significant increase in patent applications for non-peptide bradykinin B2 receptor antagonists was observed.
- These non-peptide antagonists represent a new class of compounds distinct from previously known peptide antagonists.
- The patent literature indicates active research and development in this therapeutic area.
Conclusions:
- The emergence of non-peptide bradykinin B2 antagonists marks substantial progress in the field.
- Further research into these novel antagonists is warranted for assessing their therapeutic potential.
- Patent activity suggests a growing interest in targeting bradykinin B2 receptors for various pathophysiological conditions.